Advertisement

Neonatology pp 537-539 | Cite as

Extracorporeal Membrane Oxygenation for Neonates

  • Anne Greenough
  • Munir Agha
  • Adam P. R. Smith

Abstract

Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary bypass, modified such that patients can be supported for a prolonged period of time, even weeks. ECMO is not a treatment, but rather supports the patient until their lung and/or cardiac function improves. ECMO was developed for use in adult patients, but abandoned when initial trials failed to demonstrate that it improved survival advantage over that achieved by conventional respiratory support [1]. Subsequently, Bartlett and colleagues demonstrated the potential of ECMO for neonates with severe respiratory failure. Now, many thousands of neonates have been recorded on the Extracorporeal Life Support Organisation (ELSO) database as having received ECMO. In this chapter, the techniques used and the management of a neonate on ECMO are described. In addition, the indications for ECMO and the results achieved are discussed.

Keywords

Oxygenation Index Extracorporeal Membrane Oxygenation Respiratory Support Conventional Ventilation Severe Respiratory Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Reference

  1. 1.
    Zapol WM, Snider MT, Hill JD et al (1979) Extracorporeal membrane oxygenation in severe respiratory failure. JAMA 242: 2193–2196PubMedCrossRefGoogle Scholar
  2. 2.
    UK Collaborative ECMO Trial Group (1996) UK collaborative randomized trial of neonatal extracorporeal membrane oxygenation. Lancet 248: 75–82Google Scholar
  3. 3.
    Mugford M, Elbourne D, Field D (2008) Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev 3:CD001340PubMedGoogle Scholar
  4. 4.
    Frenckner B, Radell P (2008) Respiratory failure and extracorporeal membrane oxygenation. Semin Pediatr Surg 17: 34–45PubMedCrossRefGoogle Scholar
  5. 5.
    Bennett CC, Johnson A, Filed DJ and the UK Collaborative ECMO Group (2001) UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. Lancet 357: 1094–1096PubMedCrossRefGoogle Scholar
  6. 6.
    McNally H, Bennett CC, Elbourne D, UK Collaborative ECMO Group (2006) United Kingdom Collaborative Randomised Trial of Neonatal Extracorporeal Membrane Oxygenation: follow-up to age 7 years. Pediatrics 117: e845–e854PubMedCrossRefGoogle Scholar
  7. 7.
    Beardsmore C, Dundas I, Poole K et al (2000) Respiratory function in survivors of the United Kingdom Extracorporeal Membrane Oxygenation Trial. Am J Respir Crit Care Med 161: 1129–1135PubMedGoogle Scholar
  8. 8.
    Petrou S, Bischof M, Bennett C et al (2006) Cost effectiveness of neonatal extracorporeal membrane oxygenation based on 7 year results from the United Kingdom collaborative ECMO trial. Pediatrics 117: 1640–1649PubMedCrossRefGoogle Scholar
  9. 9.
    Hitz SR, Suttner DM, Sheehan AM (2000) Decreased use of extracorporeal membrane oxygenation (ECMO): how new treatments have affected ECMO utilisation. Pediatrics 106: 1339–1343CrossRefGoogle Scholar
  10. 10.
    Coppola CP, Tyree M, Larry K, DiGeronimo R (2008) A 22 year experience in global transport extracorporeal membrane oxygenation. J Pediatr Surg 43: 46–52PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • Anne Greenough
    • 1
  • Munir Agha
  • Adam P. R. Smith
  1. 1.Division of Asthma, Allergy and Lung Biology MRC & Asthma UK Centre in Allergic Mechanisms of AsthmaKing’s College LondonLondonUK

Personalised recommendations